The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 6, 2012, Pages 820-823

  Garavito, Giovanny ^a   Bertani, Stéphane ^b,c   Quiliano, Miguel ^d   Valentin, Alexis ^b   Aldana, Ignacio ^d   Deharo, Eric ^b,e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Hôpital Purpan   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Peru)

^d UNIVERSITY OF NAVARRA   (Spain)

^e CNRS   (France)

Author keywords

Antimalarials; Drug combination; Methylene blue

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; ENZYME INHIBITOR; METHYLENE BLUE; PYRIMETHAMINE; QUININE;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; MALARIA; MALE; METHODOLOGY; MOUSE; PLASMODIUM BERGHEI;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; MALARIA; MALE; METHYLENE BLUE; MICE; PLASMODIUM BERGHEI; PYRIMETHAMINE; QUININE;

PLASMODIUM BERGHEI; RODENTIA;

EID: 84867002414     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000600019     Document Type: Article

References (34)

1. Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, Rosenthal PJ, D'Alessandro U 2011. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J 10: 144.
2. Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer RH, Becker K 2005. In vitro assessment of methylene blue on CQ-sensitive and resistant Plasmodium falciparum strains reveals synergistic action with artemisinins. Antimicrob Agents Chemother 49: 4592-4597.
3. Atamna H, Ginsburg H 1997. The malaria parasite supplies glutathione to its host cell. Investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur J Biochem 250: 670-679.
4. Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg H 1996. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol 51: 693-700.
5. Baird JK 2005. Effectiveness of antimalarial drugs. N Engl J Med 352: 1565-1577.
6. Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K, Gromer S 2008. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother 52: 183-191.
7. Färber PM, Arscott LD, Williams CH, Becker K, Schirmer RH 1998. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett 422: 311-314.
8. Ferreira 1893. Treatment of malaria with methylene blue. Lancet: 821-822.
9. Garavito G 2007. Etude pharmacologique expérimentale de l'activité antipaludique d'un composé de synthèse: le chlorure de methyl-thioninium, PhD Thesis, Université Toulouse III/Paul Sabatier École Doctorale BSB, IOP Publishing Physics, Toulouse, 155 pp.
10. Garavito G, Bertani S, Deharo E 2008. Complementary findings on the antimalarial activity and toxicity of methylene blue. Vitae 15: 91-95.
11. Garavito G, Bertani S, Rincon J, Maurel S, Monje MC, Landau I 2007a. Blood schizontocidal activity of methylene blue in combination with antimalarials against Plasmodium falciparum. Parasite 14: 135-140.
12. Garavito G, Monje MC, Maurel S, Valentin A, Nepveu F, Deharo E 2007b. A non-radiolabeled heme-GSH interaction test for the screening of antimalarial compounds. Exp Parasitol 116: 311-313.
13. Ginsburg H, Atamna H 1994. The redox status of malaria-infected erythrocytes: an overview with an emphasis on unresolved problems. Parasite 1: 5-13.
14. Guttmann P, Ehrlich P 1891. Guttmann ueber die wirkung des methylen-blau bei malaria. Berlin Klin Wochenschr 28: 953-956.
15. Legorreta-Herrera M, Retana-Ugalde R, Ventura-Gallegos JL, Narváez V 2010. Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug? Exp Parasitol 126: 381-388.
16. Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S 2006. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. J Antimicrob Chemother 58: 52-58.
17. Mandi G, Witte S, Meissner P, Coulibaly B, Mansmann U, Rengelshausen J 2005. Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Trop Med Int Health 10: 32-38.
18. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U 2006. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J 5: 84.
19. Meissner PE, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J 2005. Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso. Malar J 4: 45-54.
20. Peters W 1987. Chemotherapy and drug resistance in malaria, 2nd ed., Academic Press, London, 1100 pp.
21. Peters W, Robinson BL 1999. Handbook of animal models of infection, Academic Press, New York, 1136 pp.
22. Peterson DW, Wellems TE 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 9114-9118.
23. Plasmo DB 2005. [database on the Internet]. The plasmodium genome resource. Expression of plasmodial glutathione reductase. [cited 2005 Nov 17]. Available from: plasmodb.org/.
24. Plowe C 2001. Folate antagonists and mechanisms of resistance. In PJ Rosenthal, Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery, Humana Press Inc, New Jersey, p. 173.
25. Sarma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus PA 2003. Glutathione reductase of the malarial parasite Plasmodium falciparum: crystal structure and inhibitor development. J Mol Biol 328: 893-907.
26. Schirmer RH, Adler H, Pickhardt M, Mandelkow E 2011. "Lest we forget you - methylene blue". Neurobiol Aging 32: 2325.
27. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, Eubel J 2003. Methylene blue as an antimalarial agent. Redox Rep 8: 272-275.
28. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA 1995. Antimalarial dyes revisited: xanthenes, azines, oxazines and thiazines. Antimicrob Agents Chemother 39: 2671-2677.
29. Warr WA 2009. Fragment-based drug discovery. J Comput Aided Mol Des 23: 453-458.
30. Wermuth C 2004. Selective optimization of side effects: another way for drug discovery. J Med Chem 47: 1303-1314.
31. WHO - World Health Organization 2001. Antimalarial drug combination therapy. Report of a WHO technical consultation, WHO, Geneva, 36 pp.
32. WHO - World Health Organization 2010. [homepage on the Internet]. WHO guidelines for the treatment of malaria [cited 2011 Jun 11]. Available from: e-linkurlwho.int/malaria/url/e-link.
33. WHO - World Health Organization 2011. [homepage on the Internet]. Malaria. WHO-TDR Special Programme for Research and Training in Tropical Diseases. [cited 2011 March 10]. Available from: apps.who.int/tdr/svc/diseases/malaria.
34. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P 2003. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol 10: 357-365.